Clinical Trial

The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

Study acronym: DEXREM
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.
Trial Details
NCT Number NCT06684197
Lead Sponsor Ciusss de L'Est de l'Île de Montréal
Conditions Dexmedetomidine, Total Intravenous Anesthesia, Remifentanil Consumption, Remifentanil, Laparoscopic Abdominal Surgery
Enrollment 72 participants
Start Date 2024-11
Primary Completion 2025-11 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2024-11-12